Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP (POINT)
Double-blind, Placebo-controlled, Randomised, Multicentre, Adaptive, Two-stage Phase 2/3 Study Evaluating Safety and Efficacy of Three Dosages of NewGam in CIDP Patients
Sponsor: Octapharma
Terminated
Study Terminated.priority changes in product development.
Other terminated trials from Octapharma
Other Chronic Inflammatory Demyelinating Polyradiculoneuropathy trials with similar outcome
Browse all Chronic Inflammatory Demyelinating Polyradiculoneuropathy trials
A PHASE2/PHASE3 clinical study on Chronic Inflammatory Demyelinating Polyradiculoneuropathy, this trial is terminated or withdrawn. The trial is conducted by Octapharma and has accumulated 7 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Apr 2022 — Jul 2024 [monthly]
Terminated PHASE2_PHASE3
-
Jan 2021 — Apr 2022 [monthly]
Terminated PHASE2_PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2_PHASE3
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2_PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2_PHASE3
First recorded
Oct 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Octapharma
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.